SlideShare a Scribd company logo
1 of 15
Download to read offline
Cardiac Safety
Testing Services
Why Cardiac Safety Testing?

  S7B Guidance
  Objective
  −   Identify potential of a test substance or its metabolites to delay ventricular
      repolarization.
  −   Relate extent of delayed ventricular repolarization to concentrations of a test
      substance and its metabolites.
  Components that contribute to an assessment of cardiac risk
  −   In Vitro IKr Assay
       – effect on native or expressed IKr (such as hERG)
  −   In Vivo QT Assay
       – effect on QT interval
       – this assay can be designed to meet the objective of both the ICH S7A (cardiovascular
         core battery) and S7B
Ion Channels that Contribute to Cardiac Action Potential




                              voltage
                                               K+ Channel Block
                                        time
                                               Ca2+ Channel Block

                                               Na+ Channel Block

                                                Normal AP


  Inhibition of cardiac ion currents can alter QT interval, cause arrhythmia or death


      Discovery Safety Testing: Detect cardiac safety liabilities early.
Cardiac Safety Testing Services

                       Radioligand Binding Assays (Pharmacology, Taiwan)
                        −   Ideal for early hit selection profiling
Information Value




                       Cellular patch clamp assays (Pharmacology, Bothell)
                        −   Automated Patch Clamp (APC) with PatchXpress
                              – cost-effective technology providing a medium-throughput method usually used in
                                discovery stage after hit selection




                       Tissue Assays (Pharmacology, Taiwan)
                        −   L-Type Calcium channel Atrial Inotropy


                       In Vivo Assays – (Pharmacology, Taiwan and DSA, Lyon)
                        −   - Cardiovascular, QTc Interval




                                                                                                                 4
Ion Channel Testing Services

 Services at Bothell Site
  Non-GLP (10 day TAT)
   - Cardiac
       – hERG (Kv11.1)
       – hNav1.5
       – hCav1.2
   - Immuno-suppression and Obesity
       – hKv1.3




                                      5
Functional Ion Channel Services in Bothell

Discovery Safety Testing                     Fail Early
Crucial attributes for discovery assays:
       Fast
           10-day Turnaround time on Automated Patch Clamp (PatchXpress)
        assays

       Medium- to High-throughput capacity
          Automated Patch Clamp (PatchXpress) assays are medium-throughput at
        modest cost compared to conventional patch clamp

       Predictive of clinical outcome
              Over-expressed human cardiac ion channels that play central role in AP
                 hKv11.1 (hERG)
                 hNav1.5
                 hCav1.2
          Assays validated against drugs with known cardiac liabilities or effects;
                compare favorably with conventional patch clamp
hERG Validation (PatchXpress)
hERG Validation (PatchXpress)
                                                  hERG validation studies with
                                                     control compounds
                                       100                                         Astemizole
                                                                                   Cisapride



                  Percent of Control
                                        75                                         E4031
                                                                                   Haloperidol
                                                                                   Ketoconozole
                                        50
                                                                                   Pimozide
                                                                                   Quinidine
                                        25
                                                                                   Risperidone
                                                                                   Terfenadine
                                         0                                         Verapamil
                                             -9      -8      -7   -6   -5     -4
                                                                                   Moxifloxacine
                                                          Log Compound [uM]
                                  Assay comparison
                                     IC 50 (nM)
                    Patch Express    Conventional Patch Clamp                          Radioligand Binding
     Astemizole        13 + 2                   26                                            15
     Cisapride*        13 + 1                   45                                           158
     E4031             32 + 4                 18-36                                          75
     Haloperidol       90 + 21                  93                                           250
     Ketoconozole 2,340 + 250             1920-4700                                        19050
     Moxifloxacine 39,167 + 4,061        41,000-170,000                                      NA
     Pimozide          12 + 4                   18                                            53
     Quinidine       760 + 91               300-1000                                       13155
     Risperidone     379 + 59                  394                                          5865
     Terfenadine       38 + 7                28-56                                          127
     Verapamil       535 + 46                140-830                                        5600
      * - IC50 curve for Cisapride is not representative of current data.
hERG Validation (PatchXpress)

Comparison of PatchXpress data to conventional patch clamp (Literature values)
Nav1.5 Validation (PatchXpress)

          -10 mV                                 Voltage Clamp
                                                    Protocol
-120 mV



     A
                   1 nA

                   3 ms
                                                        1



                                     -75   -50    -25        25   50   75

                          B                             -1
                               0.5 nA
                                                        -2
                              5 ms

                                                        -3
Nav1.5 Validation (PatchXpress)
                                     hNav 1.5 validation studies with
                      100                control compounds
                                                                 Rank Order of Potency IC50 (uM)

                                                                        Dibucaine      0.149 + 0.054
                       75
                                                                        Imipramine     0.676 + 0.061
 Percent of Control




                                                                        Terfenadine    0.996 + 0.22


                       50                                               TTX              6.6 + 1.3

                                                                        Flecainide      7.58 + 1.3

                                                                        Veratridine      7.6 + 1.7


                       25                                               Quinidine      18.8 + 4.6

                                                                        Lidocaine       41.4 + 6.5




                            0
                                -8     -7       -6     -5   -4           -3

                                            Log Compound
                                            [uM]
Nav1.5 Validation (PatchXpress)
                                                                 PX pIC50 vs. RBA pIC50


                              8.00
                                                 y = 0.9863x + 0.2804
                                                        2
                                                      R = 0.8216

                              7.00
                                                                                              Dibucaine
PatchXpress (PX) pIC50 (nM)




                                                                             Imipramine

                              6.00                                                                 Terfenadine



                                                                                    Propranolol

                              5.00                                              Veratridine
                                                                        Flecanide
                                         Lidocaine

                              4.00




                              3.00
                                  3.00          4.00                5.00                    6.00                 7.00   8.00
                                                           Radioligand Binding Assay (RBA) pIC50 (nM)
Cav1.2 Validation (PatchXpress)

                       Cardiac Ca2+ channel hCav1.2
                                                           +10 mV
                                                                                      -40 mV

              -80 mV



                       2 nA

              10 ms

                                                           1


                                      Normalized Current
                                                           .8
                                                           .6
                                                           .4
                                                           .2
 0.1 nA
   0.2 nA

            10 ms
                                                            -40 -20 0        20 40   60
                                                                   Test pulse (mV)
Cav1.2 Validation (PatchXpress)

                            hCav 1.2 validation studies with
                                 control compounds                             IC50 (µM)
                                                                                     µ
                      100                                       Bepridil         1.19
                                                                                 0.87
 Percent of Control




                                                                Nitrendipine
                       75                                       Nicardipine      0.114

                                                                Nifedipine       0.138
                       50
                                                                Lacidipine       0.177

                       25                                       Diltiazem        36.5
                                                                Nimodipine       0.824
                        0                                       Isradipine       0.0535
                             -9   -8   -7   -6   -5   -4   -3
                                   Log Compound [uM]
Cav1.2 Validation (PatchXpress)
                         IC50 correlation between the PatchXpress 7000A vs. referenced
                                         conventional patch-clamp results.

                                                   Conventional pIC50 vs. PX pIC50

                   8.5
                               Spearman r = 0.90, p <0.01
                   8.0

                   7.5
                                                                                      Nitrendipine
PX log pIC50(nM)




                   7.0                                                                                                     Isradipine
                                                                                    Nifedipine
                   6.5                                                Nicardipine                      Lacidipine

                   6.0                                                               Nimodipine
                                                                              Bepridil
                   5.5

                   5.0

                   4.5             Diltiazem
                   4.0
                         4.0     4.5         5.0            5.5         6.0           6.5            7.0       7.5   8.0         8.5
                                                                  Conventional log pIC50(nM)

More Related Content

Similar to Cardiac Safety Screening 2009

Sevilla may 2012 nutrition & inflammation
Sevilla may 2012 nutrition & inflammationSevilla may 2012 nutrition & inflammation
Sevilla may 2012 nutrition & inflammationNorwich Research Park
 
Biochain PCR Products
Biochain PCR ProductsBiochain PCR Products
Biochain PCR Productsbiochain
 
hERG SOT Poster 2010
hERG SOT Poster 2010hERG SOT Poster 2010
hERG SOT Poster 2010ShiminWang
 
hERG SOT Poster 2010
hERG SOT Poster 2010hERG SOT Poster 2010
hERG SOT Poster 2010karenbernards
 
Regulation of GADD45a
Regulation of GADD45aRegulation of GADD45a
Regulation of GADD45aDonna Johnson
 
Ligandbiasslideset 120313210323-phpapp02
Ligandbiasslideset 120313210323-phpapp02Ligandbiasslideset 120313210323-phpapp02
Ligandbiasslideset 120313210323-phpapp02Patty Ahrweiler
 
22 atualização tratamento sistêmico
22   atualização tratamento sistêmico22   atualização tratamento sistêmico
22 atualização tratamento sistêmicoONCOcare
 
Improvement in Protein A Resin Lifetime
Improvement in Protein A Resin LifetimeImprovement in Protein A Resin Lifetime
Improvement in Protein A Resin LifetimeMilliporeSigma
 
Improvement in Protein A Resin Lifetime
Improvement in Protein A Resin LifetimeImprovement in Protein A Resin Lifetime
Improvement in Protein A Resin LifetimeMerck Life Sciences
 
neoplex pcr test kit [genematrix] compatible instruments for neoplex(gene_mat...
neoplex pcr test kit [genematrix] compatible instruments for neoplex(gene_mat...neoplex pcr test kit [genematrix] compatible instruments for neoplex(gene_mat...
neoplex pcr test kit [genematrix] compatible instruments for neoplex(gene_mat...HK HuZef
 
Generacer manual
Generacer manualGeneracer manual
Generacer manualgsaldania
 
Gallo et al (iser 2012)
Gallo et al (iser 2012)Gallo et al (iser 2012)
Gallo et al (iser 2012)juanedgal
 
Thesis presentation gm dt480.4 p
Thesis presentation gm dt480.4 pThesis presentation gm dt480.4 p
Thesis presentation gm dt480.4 pGavinMDublin
 
Innovations in coagulation testing
Innovations in coagulation testingInnovations in coagulation testing
Innovations in coagulation testingderosaMSKCC
 
Eustachian Tube Stent
Eustachian Tube StentEustachian Tube Stent
Eustachian Tube Stentgpye_2000
 
Separation of MEthylated Peptidic Standards by HPLC
Separation of MEthylated Peptidic Standards by HPLCSeparation of MEthylated Peptidic Standards by HPLC
Separation of MEthylated Peptidic Standards by HPLCguest83401cb
 

Similar to Cardiac Safety Screening 2009 (20)

Sevilla may 2012 nutrition & inflammation
Sevilla may 2012 nutrition & inflammationSevilla may 2012 nutrition & inflammation
Sevilla may 2012 nutrition & inflammation
 
Biochain PCR Products
Biochain PCR ProductsBiochain PCR Products
Biochain PCR Products
 
hERG SOT Poster 2010
hERG SOT Poster 2010hERG SOT Poster 2010
hERG SOT Poster 2010
 
hERG SOT Poster 2010
hERG SOT Poster 2010hERG SOT Poster 2010
hERG SOT Poster 2010
 
Regulation of GADD45a
Regulation of GADD45aRegulation of GADD45a
Regulation of GADD45a
 
Ligandbiasslideset 120313210323-phpapp02
Ligandbiasslideset 120313210323-phpapp02Ligandbiasslideset 120313210323-phpapp02
Ligandbiasslideset 120313210323-phpapp02
 
Fertilidad.ppt
Fertilidad.pptFertilidad.ppt
Fertilidad.ppt
 
Reactivo de amilasa
Reactivo de amilasaReactivo de amilasa
Reactivo de amilasa
 
22 atualização tratamento sistêmico
22   atualização tratamento sistêmico22   atualização tratamento sistêmico
22 atualização tratamento sistêmico
 
Improvement in Protein A Resin Lifetime
Improvement in Protein A Resin LifetimeImprovement in Protein A Resin Lifetime
Improvement in Protein A Resin Lifetime
 
Improvement in Protein A Resin Lifetime
Improvement in Protein A Resin LifetimeImprovement in Protein A Resin Lifetime
Improvement in Protein A Resin Lifetime
 
neoplex pcr test kit [genematrix] compatible instruments for neoplex(gene_mat...
neoplex pcr test kit [genematrix] compatible instruments for neoplex(gene_mat...neoplex pcr test kit [genematrix] compatible instruments for neoplex(gene_mat...
neoplex pcr test kit [genematrix] compatible instruments for neoplex(gene_mat...
 
Prez Baljaa09
Prez Baljaa09Prez Baljaa09
Prez Baljaa09
 
Generacer manual
Generacer manualGeneracer manual
Generacer manual
 
Gallo et al (iser 2012)
Gallo et al (iser 2012)Gallo et al (iser 2012)
Gallo et al (iser 2012)
 
Thesis presentation gm dt480.4 p
Thesis presentation gm dt480.4 pThesis presentation gm dt480.4 p
Thesis presentation gm dt480.4 p
 
Innovations in coagulation testing
Innovations in coagulation testingInnovations in coagulation testing
Innovations in coagulation testing
 
Ap2 Alpha
Ap2 AlphaAp2 Alpha
Ap2 Alpha
 
Eustachian Tube Stent
Eustachian Tube StentEustachian Tube Stent
Eustachian Tube Stent
 
Separation of MEthylated Peptidic Standards by HPLC
Separation of MEthylated Peptidic Standards by HPLCSeparation of MEthylated Peptidic Standards by HPLC
Separation of MEthylated Peptidic Standards by HPLC
 

Cardiac Safety Screening 2009

  • 2. Why Cardiac Safety Testing? S7B Guidance Objective − Identify potential of a test substance or its metabolites to delay ventricular repolarization. − Relate extent of delayed ventricular repolarization to concentrations of a test substance and its metabolites. Components that contribute to an assessment of cardiac risk − In Vitro IKr Assay – effect on native or expressed IKr (such as hERG) − In Vivo QT Assay – effect on QT interval – this assay can be designed to meet the objective of both the ICH S7A (cardiovascular core battery) and S7B
  • 3. Ion Channels that Contribute to Cardiac Action Potential voltage K+ Channel Block time Ca2+ Channel Block Na+ Channel Block Normal AP Inhibition of cardiac ion currents can alter QT interval, cause arrhythmia or death Discovery Safety Testing: Detect cardiac safety liabilities early.
  • 4. Cardiac Safety Testing Services Radioligand Binding Assays (Pharmacology, Taiwan) − Ideal for early hit selection profiling Information Value Cellular patch clamp assays (Pharmacology, Bothell) − Automated Patch Clamp (APC) with PatchXpress – cost-effective technology providing a medium-throughput method usually used in discovery stage after hit selection Tissue Assays (Pharmacology, Taiwan) − L-Type Calcium channel Atrial Inotropy In Vivo Assays – (Pharmacology, Taiwan and DSA, Lyon) − - Cardiovascular, QTc Interval 4
  • 5. Ion Channel Testing Services Services at Bothell Site Non-GLP (10 day TAT) - Cardiac – hERG (Kv11.1) – hNav1.5 – hCav1.2 - Immuno-suppression and Obesity – hKv1.3 5
  • 6. Functional Ion Channel Services in Bothell Discovery Safety Testing Fail Early Crucial attributes for discovery assays: Fast 10-day Turnaround time on Automated Patch Clamp (PatchXpress) assays Medium- to High-throughput capacity Automated Patch Clamp (PatchXpress) assays are medium-throughput at modest cost compared to conventional patch clamp Predictive of clinical outcome Over-expressed human cardiac ion channels that play central role in AP hKv11.1 (hERG) hNav1.5 hCav1.2 Assays validated against drugs with known cardiac liabilities or effects; compare favorably with conventional patch clamp
  • 8. hERG Validation (PatchXpress) hERG validation studies with control compounds 100 Astemizole Cisapride Percent of Control 75 E4031 Haloperidol Ketoconozole 50 Pimozide Quinidine 25 Risperidone Terfenadine 0 Verapamil -9 -8 -7 -6 -5 -4 Moxifloxacine Log Compound [uM] Assay comparison IC 50 (nM) Patch Express Conventional Patch Clamp Radioligand Binding Astemizole 13 + 2 26 15 Cisapride* 13 + 1 45 158 E4031 32 + 4 18-36 75 Haloperidol 90 + 21 93 250 Ketoconozole 2,340 + 250 1920-4700 19050 Moxifloxacine 39,167 + 4,061 41,000-170,000 NA Pimozide 12 + 4 18 53 Quinidine 760 + 91 300-1000 13155 Risperidone 379 + 59 394 5865 Terfenadine 38 + 7 28-56 127 Verapamil 535 + 46 140-830 5600 * - IC50 curve for Cisapride is not representative of current data.
  • 9. hERG Validation (PatchXpress) Comparison of PatchXpress data to conventional patch clamp (Literature values)
  • 10. Nav1.5 Validation (PatchXpress) -10 mV Voltage Clamp Protocol -120 mV A 1 nA 3 ms 1 -75 -50 -25 25 50 75 B -1 0.5 nA -2 5 ms -3
  • 11. Nav1.5 Validation (PatchXpress) hNav 1.5 validation studies with 100 control compounds Rank Order of Potency IC50 (uM) Dibucaine 0.149 + 0.054 75 Imipramine 0.676 + 0.061 Percent of Control Terfenadine 0.996 + 0.22 50 TTX 6.6 + 1.3 Flecainide 7.58 + 1.3 Veratridine 7.6 + 1.7 25 Quinidine 18.8 + 4.6 Lidocaine 41.4 + 6.5 0 -8 -7 -6 -5 -4 -3 Log Compound [uM]
  • 12. Nav1.5 Validation (PatchXpress) PX pIC50 vs. RBA pIC50 8.00 y = 0.9863x + 0.2804 2 R = 0.8216 7.00 Dibucaine PatchXpress (PX) pIC50 (nM) Imipramine 6.00 Terfenadine Propranolol 5.00 Veratridine Flecanide Lidocaine 4.00 3.00 3.00 4.00 5.00 6.00 7.00 8.00 Radioligand Binding Assay (RBA) pIC50 (nM)
  • 13. Cav1.2 Validation (PatchXpress) Cardiac Ca2+ channel hCav1.2 +10 mV -40 mV -80 mV 2 nA 10 ms 1 Normalized Current .8 .6 .4 .2 0.1 nA 0.2 nA 10 ms -40 -20 0 20 40 60 Test pulse (mV)
  • 14. Cav1.2 Validation (PatchXpress) hCav 1.2 validation studies with control compounds IC50 (µM) µ 100 Bepridil 1.19 0.87 Percent of Control Nitrendipine 75 Nicardipine 0.114 Nifedipine 0.138 50 Lacidipine 0.177 25 Diltiazem 36.5 Nimodipine 0.824 0 Isradipine 0.0535 -9 -8 -7 -6 -5 -4 -3 Log Compound [uM]
  • 15. Cav1.2 Validation (PatchXpress) IC50 correlation between the PatchXpress 7000A vs. referenced conventional patch-clamp results. Conventional pIC50 vs. PX pIC50 8.5 Spearman r = 0.90, p <0.01 8.0 7.5 Nitrendipine PX log pIC50(nM) 7.0 Isradipine Nifedipine 6.5 Nicardipine Lacidipine 6.0 Nimodipine Bepridil 5.5 5.0 4.5 Diltiazem 4.0 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 Conventional log pIC50(nM)